EMElizabeth N. Madva

Elizabeth N. Madva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth N. Madva has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The WISH 2.0 Intervention for Irritable Bowel Syndrome: Protocol for a Pilot Randomized Controlled Trial

    by Elizabeth N Madva, Jeff C Huffman, Helen Burton-Murray, Emmett McGranaghan, Megan Bidgood, Jenny Y Gan, Benjamin Wasserman, Emily H Feig, Brian Healy, Kyle Staller, et al.

    Background: There is a critical need for acceptable, scalable, and mechanistically targeted behavioral health interventions for irritable bowel syndrome (IBS), known as brain-gut behavior therapies (BGBTs). Although positive psychology (PP) interventions, which focus on the cultivation of positive psychological well-being, have been linked to improved health outcomes across diverse medical populations, they have not yet been investigated in IBS. To address this gap, we developed WISH (Well-Being in IBS: Strengths and Happiness), a novel, 9-week, phone-delivered PP-based BGBT for individuals with IBS. Objective: This randomized controlled trial (RCT) aims to evaluate the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of a 9-week phone-delivered PP intervention for IBS compared with a time- and attention-matched educational control. Methods: The WISH 2.0 trial is a parallel-group, 9-week pilot RCT that aims to enroll 50 adults meeting Rome IV criteria for IBS. Participants are randomized (1:1), stratified by IBS subtype and gender, to either the WISH 2.0 intervention or an educational control condition. Both conditions consist of 9 weekly 30-minute phone sessions accompanied by weekly manualized exercises. Primary outcomes are feasibility (proportion completing ≥6 of 9 sessions) and acceptability (weekly ease and utility ratings). Secondary outcomes include WISH 2.0’s preliminary effects on health-related, health behavior, and psychological outcomes, assessed at 4 time points: baseline, intervention midpoint, the postintervention assessment, and the 3-month postintervention assessment. Candidate gut-brain mechanisms that might underlie WISH 2.0’s effects, including changes in autonomic function (heart rate variability), interoception (self-report measure), gene expression (whole transcriptome RNA sequencing), and immune system activity (serum inflammatory biomarkers), will be explored before and after the intervention. Results: The trial was approved by the Mass General Brigham Institutional Review Board and prospectively registered at ClinicalTrials.gov in March 2025. Funding was awarded in June 2025. Following a study start-up period, recruitment commenced in October 2025 and is ongoing. As of July 2026, 20 participants have been enrolled. Study completion is anticipated in August 2028. Conclusions: This trial will determine the feasibility and acceptability of WISH 2.0, a novel PP intervention for IBS. Comparative results between WISH 2.0 and an educational control, including the possibility of equivalent outcomes, will provide important mechanistic insights and facilitate further optimization of BGBTs for IBS, informing a future fully powered efficacy trial.

  • Provider‐Prescribed Restrictive Diets in Patients With Eating Disorders Presenting for Gastroenterology Care

    by Armand Amini, Mia Dekel, Mariana N. Almeida, Micaela Atkins, Isabelle Garcia‐Fisher, Elizabeth N. Madva, Helen Burton‐Murray, Kyle Staller

    Introduction: Despite considerable evidence and patient demand, restrictive diets for gastrointestinal (GI) disorders may be harmful in those with comorbid eating disorders (EDs). We identified the frequency and characteristics of provider‐recommended restrictive diets among those with EDs seeking GI care. Methods: Using a preexisting cohort of patients who had a GI encounter from 2010 to 2020 with a GI diagnosis and ED diagnosis (either diagnosed before or after initial GI encounter), we conducted a retrospective analysis of restrictive diet prescriptions within 12 months of initial GI consult as well as diet type, provider subspecialty, and types of ED and GI diagnoses. Results: From a cohort of 610 patients, we found 285 patients meeting our inclusion criteria; 50 (17.5%) were prescribed restrictive diets within 12 months of their GI consult by GI providers. Disorders of gut‐brain interaction were the most common GI diagnoses overall ( n = 169, 59.3%). Of those with a pre‐existing ED ( n = 188), 30 (16.0%) were prescribed a restrictive diet, and of those with a subsequently diagnosed ED ( n = 97), 20 (20.6%) were prescribed a restrictive diet. Among patients with preexisting EDs, 69 (36.7%) were not in remission at the time of consultation. Of those with preexisting EDs who were prescribed a restrictive diet, 17/30 (57.7%) were not in remission. Conclusion: We found that 16% of patients with an ED history were prescribed a restrictive diet by their gastroenterologist, including those not in remission. Further research is needed on the potential risk of restrictive diets in facilitating ED behavior.

  • Nurse practitioner‐delivered cognitive–behavioral treatment as a novel implementation route for irritable bowel syndrome: A proof of concept

    by Helen Burton Murray, Imani Weeks, Andrea Thurler, Samantha Calabrese, Mary Kate Lapinel, Elizabeth N Madva, Kyle Staller, Laurie Keefer, Braden Kuo

    Background: Exposure‐based cognitive–behavioral therapy (exposure‐CBT) is efficacious for irritable bowel syndrome (IBS). However, few patients receive exposure‐CBT due to a lack of behavioral health providers trained in brain–gut behavior therapies. Nurse practitioners (NPs) could fill a critical need for scalable delivery methods. In a pragmatic investigation of a 5‐session NP‐delivered exposure‐CBT for adults with Rome IV‐defined IBS, we evaluated treatment feasibility and acceptability and explored changes clinical outcomes.Methods: Exposure‐CBT was delivered as part of routine care involving four sessions every other week and a 2‐month booster session. Patients could electively participate in an observational study including pre‐, mid‐, and post‐treatment surveys and a post‐treatment qualitative interview. Independently coded ratings of NP treatment protocol adherence and competence ratings were completed from audio recordings, rated on a 1 (not at all) to 5 (completely) scale.Results: Twenty‐five patients consented (ages 22‐67 years; 76% female; 48% IBS‐diarrhea predominant). There was high feasibility—adherence average = 4.1, NP competence average = 4.8, 72% treatment completion, 93% satisfaction scores ≥3. Treatment satisfaction was high (rated as 4/4 “very satisfied” by n = 9 and as 3/4 “mostly satisfied” by n = 5). There were improvements in clinical outcomes across treatment with large effects for IBS‐symptom severity (−53%; Hedge's g = 1.0; 95% confidence interval [CI] = 0.5, 1.5) and IBS quality of life (+31%; Hedge's g = 0.8; 95% CI = 0.4, 1.2).Conclusions: NP‐delivered exposure‐CBT for IBS was initially feasible and acceptable with promising clinical improvements. Findings will inform a future NIH Stage 1B/ORBIT Phase IIB pilot randomized control trial.


  • Positive psychological well‐being: A novel concept for improving symptoms, quality of life, and health behaviors in irritable bowel syndrome

    by Elizabeth N. Madva, Lauren E. Harnedy, Regina M. Longley, Alexandra Rojas Amaris, Crystal Castillo, Marie D. Bomm, Helen Burton Murray, Kyle Staller, Braden Kuo, Laurie Keefer, et al.

    Background: Though a growing body of research suggests that greater positive psychological well‐being in irritable bowel syndrome (IBS) may be protective, existing brain–gut behavior therapies primarily target negative psychological factors. Little is known about how positive psychological factors in IBS relate to IBS symptoms, health‐related quality of life (HRQoL), or adherence to key health behaviors, such as physical activity and diet modification. Accordingly, per the ORBIT model of behavioral treatment development for chronic diseases, we explored potential connections between psychological constructs and IBS symptoms, health behavior engagement (physical activity and dietary modification), and HRQoL in a qualitative study to inform the development of a novel brain–gut behavior therapy.Methods: Participants with IBS completed self‐report assessments and semi‐structured phone interviews about relationships between positive and negative psychological constructs, IBS symptoms, health behavior engagement, and HRQoL.Key Results: Participants (n = 23; 57% female) ranged in age from 25 to 79 (mean age = 54). IBS subtypes were similarly represented (IBS‐diarrhea [n = 8], IBS‐constipation [n = 7], and IBS‐mixed [n = 8]). Participants described opposing relationships between positive and negative psychological constructs, IBS symptoms, health behavior engagement, and HRQoL, respectively, such that experiencing positive constructs largely mitigated IBS symptoms, boosted health behavior participation, and improved HRQoL, and negative constructs exacerbated symptoms, reduced health behavior participation, and worsened HRQoL.Conclusions and Inferences: Participants with IBS linked greater positive psychological well‐being to moderated IBS symptoms and better HRQoL and health behavior participation. An intervention to cultivate greater well‐being may be a novel way to mitigate IBS symptoms, boost health behavior participation, and improve HRQoL in IBS.


  • Positive psychological well-being and clinical characteristics in IBS: A systematic review

    by Elizabeth N. Madva, Monika Sadlonova, Lauren E. Harnedy, Regina M. Longley, Hermioni L. Amonoo, Emily H. Feig, Rachel A. Millstein, Juliana Zambrano, Alexandra Rojas Amaris, Jane Jurayj, et al.


  • History of trying exclusion diets and association with avoidant/restrictive food intake disorder in neurogastroenterology patients: A retrospective chart review

    by Micaela Atkins, Claire Zar‐Kessler, Elizabeth N. Madva, Kyle Staller, Kamryn T. Eddy, Jennifer J. Thomas, Braden Kuo, Helen Burton Murray

    Background: Exclusion diets for gastrointestinal symptom management have been hypothesized to be a risk factor for avoidant/restrictive food intake disorder (ARFID; a non‐body image‐based eating disorder). In a retrospective study of pediatric and adult neurogastroenterology patients, we aimed to (1) identify the prevalence and characteristics of an exclusion diet history and (2) evaluate if an exclusion diet history was concurrently associated with the presence of ARFID symptoms.Methods: We conducted a chart review of 539 consecutive referrals (ages 6–90, 69% female) to adult (n = 410; January–December 2016) and pediatric (n = 129; January 2016–December 2018) neurogastroenterology clinics. Masked coders (n = 4) retrospectively appliedDSM‐5criteria for ARFID and a separate coder assessed documentation of exclusion diet history. We excluded patients with no documentation of diet in the chart (n = 35) or who were not orally fed (n = 9).Results: Of 495 patients included, 194 (39%) had an exclusion diet history, and 118 (24%) had symptoms of ARFID. Of reported diets, dairy‐free was the most frequent (45%), followed by gluten‐free (36%). Where documented, exclusion diets were self‐initiated by patients/parents in 66% of cases, and recommended by gastroenterology providers in 30%. Exclusion diet history was significantly associated with the presence of ARFID symptoms (OR = 3.12[95% CI 1.92–5.14],p < 0.001).Conclusions: History of following an exclusion diet was common and was most often patient‐initiated among pediatric and adult neurogastroenterology patients. As patients with self‐reported exclusion diet history were over three times as likely to have ARFID symptoms, providers should be cognizant of this potential association when considering dietary interventions.


  • Psychiatric comorbidities among adult patients with disorders of gut–brain interaction: Prevalence and relationships to treatment outcomes

    by Elizabeth N. Madva, Kyle Staller, Jeff C. Huffman, Braden Kuo, Isabelle Garcia‐Fischer, Micaela Atkins, Laurie Keefer, Christopher M. Celano, Helen Burton Murray

    Background: Little is known about the impact of psychiatric comorbidity on pharmacologic treatment outcomes, including neuromodulators (medications targeting the gut–brain axis), among adult patients with disorders of gut–brain interaction (DGBI). Accordingly, we aimed to examine associations between psychiatric comorbidity and DGBI pharmacologic treatment outcomes.Methods: In a retrospective study of consecutively referred new patients (N = 410; ages 18–90; 73% female) to a tertiary neurogastroenterology clinic in 2016 with follow‐up through 2018, relationships between psychiatric illness (any psychiatric illness, anxiety disorders, depressive disorders) and pharmacologic treatment selection (any medication, neuromodulating medication) and treatment outcomes, respectively, were examined using multivariable logistic regression, adjusting for demographics, gastrointestinal (GI) diagnoses, and pre‐existing neuromodulator use.Key Results: Anxiety disorders (35%) were the most common psychiatric comorbidity, followed by depressive disorders (29%). Patients with anxiety disorders were more likely to be prescribed a neuromodulator by their gastroenterologist (OR = 1.72 [95% CI 1.10–2.75]) yet less likely to respond to neuromodulators (OR = 0.43 [0.21–0.90]) or any GI medication (OR = 0.24 [0.12–0.50]) in fully adjusted analyses. In contrast, depressive disorders were not associated with neuromodulator prescription or response.Conclusions and Inferences: Anxiety disorders are common among patients with DGBI and significantly reduce the likelihood of GI pharmacologic treatment response to any medication prescribed, including neuromodulators.


  • A Care Management Intervention for Noncardiac Chest Pain

    by Elizabeth N. Madva, Christopher M. Celano, Sonia Kim, Margaret Bell, Azar Radfar, Nasrien E. Ibrahim, Tawseef Dar, Ariana Albanese, Ahmed Tawakol, Jeff C. Huffman

    This study describes the development, implementation, and preliminary feasibility of an 8-week multicomponent care management intervention for noncardiac chest pain.


  • Relationships Between Life Stressors, Health Behaviors, and Chronic Medical Conditions in Mid-Life Adults: A Narrative Review

    by Federico Gomez-Bernal, Federico Gomez-Bernal, Elizabeth N. Madva, Elizabeth N. Madva, Judith Puckett, Judith Puckett, Hermioni L. Amonoo, Hermioni L. Amonoo, Rachel A. Millstein, Rachel A. Millstein, et al.